BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27191996)

  • 1. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
    Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
    Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
    Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
    Coppock JD; Volaric AK; Mills AM; Gru AA
    Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
    Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
    Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
    Oktay E; Yalcin GD; Ekmekci S; Kahraman DS; Yalcin A; Degirmenci M; Dirican A; Altin Z; Ozdemir O; Surmeli Z; Diniz G; Ayhan S; Bulut G; Erdogan A; Uslu R
    J BUON; 2019; 24(2):779-790. PubMed ID: 31128036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization.
    Gafeer MM; Hosny Mohammed K; Ormenisan-Gherasim C; Choudhary F; Siddiqui MT; Cohen C
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):e86-e90. PubMed ID: 28968265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
    Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
    Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
    Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Jan; 38(1):107-112. PubMed ID: 29277762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.
    Spirina L; Avgustinovich A; Afanas'ev S; Volkov M; Dobrodeev A; Cheremisina O; Kostromitsky D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.